Clinical Trial Update: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial to assess safety, efficacy, and cellular kinetics of YTB323 in generalized myasthenia gravis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• YTB323

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Generalized Myasthenia Gravis | Phase 1, Phase 2 | Status: RECRUITING